Navigation Links
Hospital Workers Say Concessions Will Diminish Patient Care
Date:6/17/2008

at noon

The 150,000-member SEIU United Healthcare Workers-West is the largest hospital and healthcare union in the western United States and represents every type of healthcare worker, including nurses, professional, technical and service classifications. Our mission is to achieve high-quality healthcare for all.

CONTACT: Tadzio Garcia

(213) 300-8974; tgarcia@seiu-uhw.org


'/>"/>
SOURCE SEIU United Healthcare Workers-West
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. IPC The Hospitalist Company, Inc. Files Registration Statement for Proposed Offering
2. Medline Announces Nationwide Launch of Hand Hygiene Compliance Program for Hospital and Healthcare Facilities
3. Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology
4. IDC implements DR systems in eight A-Class military hospitals in Pakistan
5. The Valley Hospital in Ridgewood, NJ, Announces Historic $30 Million Gift
6. Harvard Study in Joint Commission Journal: Mortality Rates Lower in Leapfrog Hospitals
7. Alexian Brothers Hospital Network Receives American Stroke Associations Get With The Guidelines Gold Performance Achievement Award
8. National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers
9. Breast-Feeding Support Lacking at Many Hospitals, Birth Centers
10. Prevalence of US osteoprotic hip fracture hospitalizations declines despite an aging population
11. Chair of Radiology at Presbyterian Hospital of Dallas Named President of American College of Physician Executives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...e/ -- During a memorial service in the Capitol Ro...d Lieutenant Governor Catherine Baker Knoll as a l...rvice, and a tireless advocate for the people of P...d lieutenant governor, Catherine was a noted and s...r family and her faith were driving forces in her ...
(Date:11/21/2008)...Lennox-Gastaut syndrome , , FRIDAY, Nov....rufinamide) has been approved as a supplementary t...ox-Gastaut syndrome, the U.S. Food and Drug Admini...ased on results of a four-month clinical trial tha...ents who took a placebo, those who took the drug h...
(Date:11/21/2008)...t Investment And Restore Shareholder Value , ,... Dr. Stephen Joffe, Craig Joffe, and Alan Buckey t... the U.S. Securities and Exchange Commission. The... of 11.4% of LCA-Vision, Inc. (Nasdaq: LCAV ), w... correction centers in 33 states in the United Sta...
(Date:11/21/2008)...ic damage that can lead to disease , , F...ications for treating attention-deficit hyperactiv...nked to an increased risk for developing cancer, a...rs at Duke University Medical Center and the Natio...that reported biomarkers associated with an increa...
Breaking Medicine News(10 mins):Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 2Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:ADHD Medications Don't Pose Cancer Risk 2
...licy by the Government of India will now enable In...d, to practice in India, through a screening test ...aminations (An Autonomous Body of The Ministry of ...gistration is only to qualify for registration wit...
...lments that are treated with angioplasty or a tran...While in transplantation there is an ever-present ...placing a balloon in the artery causes damage to t...e system response. A new study has however, reveal...
...ers at Washington University School of Medicine ha...ombocytopenic purpura(TPP), which has offered grea... of the proteins in the blood clotting system is m..., without it, one of the other clotting proteins s...
...rtment of Dermatopathology in a University Medical...udy of 330 subjects suffering from severe seborrhe...ess of Ketoconazole// 2% and Zinc pyrithione 1% sh...tients were randomized to ketoconazole 2% shampoo ...
Other Medicine News:
(Date:11/20/2008)...LTS OF FIRST PHASE III TRIAL SHOW SIGNIFICANT, ...N DAILY FUNCTION, IN, ...d BRUSSELS, Belgium, Nov. 20 /PRNewswire-FirstCall... and UCB (Euronext Brussels: UCB),announced today...rst of two,Phase III pivotal clinical trials of s...
(Date:11/20/2008)...Newswire-FirstCall/ -- Duska Therapeutics,Inc., ...t has submitted its,pivotal Phase 3 ATPace clinic...ocol Assessment (SPA) procedure with the U.S. Food...to securing an agreement with the FDA, Duska inten...d, placebo-controlled and randomized Phase 3,clin...
(Date:11/20/2008)...20 The Scandinavian-based drug,de...sults of studies on its,lead antimicrobial candid...,the studies showed that the novel lytic peptidom...ignificantly better towards killing Staphylococcus...gold standard drugs. In,addition to this it has p...
(Date:11/19/2008)...sic findings on critical enzyme,s regulation may h...ray of disorders , , MEMPHIS, Tenn., Nov. 1...de Children,s Research Hospital have gained new in... workhorses called calpains. , , As the ce... many cellular processes, including the movement o...
Breaking Medicine Technology:Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Cradle 26 Grave 29624 1Cradle 26 Grave 29624 2Cradle 26 Grave 29624 3Video 3A CVS pharmacy and National Council on Aging Help Seniors to Find the Right Prescription for Medicare Savings 29622 1Video 3A CVS pharmacy and National Council on Aging Help Seniors to Find the Right Prescription for Medicare Savings 29622 2Video 3A CVS pharmacy and National Council on Aging Help Seniors to Find the Right Prescription for Medicare Savings 29622 3Vermont Surgeon Implants First Accommodating Crystalens in Russia 9146 1Vermont Surgeon Implants First Accommodating Crystalens in Russia 9146 2B Braun Directors Participate at First ISMP National Smart Pump Safety Summit 9144 1B Braun Directors Participate at First ISMP National Smart Pump Safety Summit 9144 2B Braun Directors Participate at First ISMP National Smart Pump Safety Summit 9144 3
...blood sugar reductions seen across range of,patien... elderly,and those at high risk of developing dia...a sulfonylurea,reinforcing efficacy in combinatio...onfirm good tolerability in humans with studies sh... in monotherapy,trials , * European regulatory dec...
...ESS WIRE)--Jun 23, 2007 - Late breaking data,prese...th Annual,Scientific Sessions showed that, when us...M) (sitagliptin) in combination with,metformin pro...erally well tolerated over 54 weeks in patients wi...tigational studies,presented also showed that JANU...
Other Medicine Technology:New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 2New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 3New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 4New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 5New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 6Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 2Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 3Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 4Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 6Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 7Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 8Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 9Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 10Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 11Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 12Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 13Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 14Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 15Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 16Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 17Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 18Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 19Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 20Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 21Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 22Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 23Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 24Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 25Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 26Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 27Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 28Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 29Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 30Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 31
High viscosity bone cement without antibiotics for digital use with an average setting time of approx. 6-8 Min., 40g of powder and 14.4g of liquid.
...x Solitaire represents the latest in green laser t... for use in both the operating room and clinic. De... Solitaire is the premium 532nm photocoagulator. ,...r system and has the flexibility to deliver up to ...
...2005A is the answer for long-term transtelephonic ...button once symptoms begin in order to record all ...mission " button, the patient sends the recorded E...ving Station (HRS) for immediate diagnosis. Use of...
...try cardiac resynchronization therapy (CRT) defibr... medical therapy offering automatic fluid status m...ncompassing the lungs and heart. This advance is e...g heart failure, since thoracic fluid accumulation...
Medicine Products: